Hawaii 2023 Regular Session

Hawaii Senate Bill SCR5

Introduced
1/25/23  

Caption

Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.

Impact

The working group is tasked with comprehensively reviewing the current federal, state, and local regulations regarding the medicinal application of psilocybin and psilocin. Moreover, it will examine scientific studies and research exploring the safety and efficacy of these compounds in mental health treatments. By pursuing this initiative, Hawaii aims to improve access to alternative therapies that could address the state's mental health crisis, which is especially relevant given the growing acknowledgment of psilocybin's potential as a breakthrough therapy for severe depression as noted by the FDA.

Summary

Senate Concurrent Resolution 5 (SCR5) requests the Hawaii Department of Health to establish a Medicinal Psilocybin and Psilocin Working Group. The aim of this group is to explore the medicinal benefits and therapeutic effects of psilocybin and psilocin, two naturally occurring compounds in certain mushrooms, which have been studied for their potential efficacy in treating various mental health conditions such as depression, anxiety disorders, and psychological distress at the end of life. The resolution recognizes the pressing need for innovative solutions in the face of a shortage of mental health professionals in Hawaii.

Contention

One notable aspect of SCR5 is its focus on creating a long-term strategic plan to ensure that psilocybin and psilocin products remain safe, accessible, and affordable for eligible adult patients. This initiative may lead to complications concerning current laws and regulations surrounding psychotropic substances, as the bill necessitates the formation of guidelines for medical professionals on prescribing these compounds. As such, the resolution reveals a commitment to exploring therapeutic methods that could modify the existing legal framework around mental health treatments in Hawaii, prompting discussions on potential implications for healthcare practices and regulatory oversight in the state.

Companion Bills

No companion bills found.

Similar Bills

HI SR3

Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.

HI SCR227

Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.

HI SCR215

Requesting The Department Of Health To Convene A Medicinal Psychedelics Right-to-try Task Force To Explore The Development Of A Program For Qualifying Terminally Ill Patients.

HI SR206

Requesting The Department Of Health To Convene A Medicinal Psychedelics Right-to-try Task Force To Explore The Development Of A Program For Qualifying Terminally Ill Patients.

MA H1858

Relative to removing criminal penalties for limited psilocybin possession

MA S1113

Relative to removing criminal penalties for limited psilocybin possession

MA H2506

Decriminalizing psilocybin as a treatment for PTSD and certain other conditions

NM SB219

Medical Psilocybin Act